Brought to you by 
Cypress Bioscience gets antipsychotic compound from BioLineRx; deal terminated
13 May 2011
Executive Summary
Cypress Bioscience Inc. (CNS therapies and personalized diagnostics) has licensed exclusive development and commercialization rights in the US, Canada, and Mexico to Israeli drug company BioLineRx Ltd.'s BL1020 (renamed CYP1020) for schizophrenia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cypress Bioscience gets antipsychotic compound from BioLineRx; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice